Bottom line Retatrutide is still in clinical trials, with early data suggesting significant weight loss potential, while semaglutide has FDA approval with proven efficacy and safety history
reducing hunger signals in the same powerful way, explained Gunter Kuhnle, a nutrition expert and food scientist at the UKs University of Reading, in an interview with the Daily Mail
This means semaglutide users often add more water (2-3mL) to keep lower doses measurable, while retatrutide users at higher doses may prefer less water (1mL) to keep injection volumes manageable
We found that the PRR for the aforementioned four types of tumors associated with exenatide/liraglutide and the first three types of tumors associated with semaglutide were greater than 1
The short answer is: likely yes, with appropriate medical supervision
Arch Bronconeumol 2020;56:506-13